IP Library › Granted Patent US 9,403,910
Granted Patent B2
US 9,403,910 · App. 13/828,419 · Granted Aug 2, 2016

Polynucleotides encoding an actriib antibody

Inventors: Ravindra Kumar (Acton, MA); Asya Grinberg (Lexington, MA); Monique Davies (Harpswell, ME); Diana Martik (Cambridge, MA); Janja Cosic (Arlington, MA); Rachel Kent (Boxborough, MA); David Buckler (Chester, NJ)
Assignees: Acceleron Pharma Inc.; Dyax Corporation
C07K16/2863C07K16/40C07K2317/21C07K2317/52C07K2317/55C07K2317/565C07K2317/71C07K2317/76C07K2317/92C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,403,910
App. No.
13/828,419
Granted
Aug 2, 2016
Kind
B2
Abstract

The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.

Claims (4)

1. An isolated polynucleotide sequence encoding an anti-ActRIIB antibody or functional fragment thereof that binds to ActRIIB between amino acids 20-134 of SEQ ID NO:1, wherein said antibody or functional fragment thereof comprises a variable heavy chain encoded by the nucleic acid sequence of SEQ ID NO: 17 and a variable light chain encoded by the nucleic acid sequence of SEQ ID NO: 18.

2. A cloning or expression vector comprising the isolated polynucleotide sequence according to claim 1 .

3. An isolated host cell comprising the vector according to claim 2 .

4. A process for the production of an antibody or functional fragment thereof that binds to ActRIIB between amino acids 20-134 of SEQ ID NO:1, comprising culturing the host cell of claim 3 and isolating the antibody or functional fragment thereof.

Continuity (2)
Continuation 13283552 · Oct 27, 2011
Related Publication 20130189269A1 · Jul 25, 2013